Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
p53-inducible cancer-associated RNA transcript 1 (PICART1)
- Target
- PICART1
- Molecular classification
- Long non-coding RNA (lncRNA), Non-coding RNA gene, Other (not a protein, not a receptor/enzyme/transcription factor)
01
Overview
PICART1 is a long non-coding RNA (lncRNA) of 2.53 kb, encoded in the human genome at 17q21.33. It is transcriptionally upregulated by the tumor suppressor p53 and acts as a tumor suppressor itself by inhibiting cancer cell proliferation, migration, and invasion through suppression of AKT/GSK3β/β-catenin and JAK2/STAT3 signaling pathways. In several cancers such as breast, colorectal, and lung cancer, PICART1 expression is downregulated, and experimental overexpression of PICART1 can inhibit tumor growth and promote apoptosis. Its reduced expression also correlates with activation of immune pathways, and it is studied as a diagnostic or prognostic marker for cancers and immune-mediated neuropathies (AIDP, CIDP). PICART1 represents an emerging therapeutic and diagnostic RNA target, though no direct targeting drugs are currently approved.
- Other names
- PICART1p53-inducible cancer-associated RNA transcript 1
02
Mechanism of action
Drugs/agents that increase p53 activity (such as RITA, doxorubicin) may upregulate PICART1; this leads to suppression of oncogenic signaling pathways (AKT/GSK3β/β-catenin, JAK2/STAT3) and tumor suppression.
03
Biological functions
Tumor suppression (suppresses cancer cell proliferation, migration, invasion)Negative regulation of AKT/GSK3β/β-catenin signalingSuppression of JAK2/STAT3 signalingCell cycle arrest (increases p21Waf/cip1, induces G2/M arrest)Promotes apoptosis in cancer cellsModulates immune response (potential involvement in immune-mediated diseases via STAT3 and cytokine modulation)
04
Disease associations
Cancer (breast, colorectal, lung cancer)Immune-mediated neuropathies (acute and chronic inflammatory demyelinating polyradiculopathy: AIDP, CIDP)Other (potential role in controlling inflammation, immune response)
05
Safety considerations
As a non-coding RNA, therapeutic approaches targeting PICART1 (such as lncRNA mimics or antisense oligonucleotides) are still experimental; safety and efficacy challenges include delivery, off-target effects, and specificityNo direct clinical safety data available since PICART1 is not yet a drug target
06
Interacting drugs
Not directly targeted by FDA-approved drugs as of 2024.
2 more in the full profile.
07
Biomarkers
Decreased PICART1 RNA expression has potential as a biomarker for cancer diagnosis and prognosis (particularly breast, colorectal, lung)Decreased PICART1 levels are being studied as candidate biomarkers for immune-mediated neuropathies (AIDP, CIDP)
Beyond the preview
Go deeper on p53-inducible cancer-associated RNA transcript 1 (PICART1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on p53-inducible cancer-associated RNA transcript 1 (PICART1).